Amundi Boosts Stock Position in Quest Diagnostics Incorporated $DGX

Key Points

• Amundi increased its Quest Diagnostics stake by 22.1% in the second quarter, bringing its holdings to 498,751 shares valued at approximately $105.7 million. Institutional investors collectively own 88.06% of DGX.
• Quest Diagnostics reported quarterly EPS of $3.12, exceeding expectations of $2.82, while revenue rose 10.2% year over year to $3.04 billion. The company issued fiscal 2026 EPS guidance of $11.05–$11.25.
• The company declared a quarterly dividend of $0.86, equivalent to an annualized $3.44 payout and a 1.5% yield. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $236.31.

Amundi grew its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 22.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 498,751 shares of the medical research company's stock after acquiring an additional 90,421 shares during the quarter. Amundi owned 0.45% of Quest Diagnostics worth $105,710,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Bank OZK bought a new stake in shares of Quest Diagnostics in the second quarter worth about $3,247,000. Assenagon Asset Management S.A. lifted its holdings in Quest Diagnostics by 39.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company's stock worth $3,265,000 after buying an additional 4,334 shares during the period. ANTIPODES PARTNERS Ltd lifted its holdings in Quest Diagnostics by 178.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company's stock worth $29,847,000 after buying an additional 110,280 shares during the period. BlackRock Inc. bought a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $1,965,923,000. Finally, International Assets Investment Management LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter worth approximately $92,000. 88.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Michael Prevoznik sold 22,677 shares of the firm's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the sale, the senior vice president directly owned 37,557 shares in the company, valued at $9,130,482.27. This trade represents a 37.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the firm's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares in the company, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock worth $8,316,493 over the last quarter. 0.88% of the stock is currently owned by corporate insiders.

Quest Diagnostics Stock Up 0.1%

NYSE:DGX opened at $235.68 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a market cap of $26.01 billion, a P/E ratio of 25.02, a P/E/G ratio of 2.15 and a beta of 0.55. Quest Diagnostics Incorporated has a fifty-two week low of $171.18 and a fifty-two week high of $247.19. The firm has a 50-day simple moving average of $229.01 and a two-hundred day simple moving average of $209.00.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to analysts' expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company's revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts predict that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be given a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics's dividend payout ratio is presently 36.52%.

Analyst Ratings Changes

Several research firms recently weighed in on DGX. Jefferies Financial Group reiterated a "buy" rating and issued a $245.00 price target on shares of Quest Diagnostics in a report on Thursday, July 23rd. Barclays raised their target price on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Robert W. Baird lifted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Mizuho boosted their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Finally, UBS Group increased their price target on shares of Quest Diagnostics from $232.00 to $245.00 and gave the stock a "neutral" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, Quest Diagnostics presently has an average rating of "Moderate Buy" and a consensus price target of $236.31.

Quest Diagnostics Profile

Quest Diagnostics Incorporated NYSE: DGX is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.

Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.